Can You Take Ivermectin and Fenbendazole Together?

No clinical trial has tested ivermectin and fenbendazole together in humans, which means there is no established safe dose, no known interaction profile, and no evidence the combination works for any human disease. What does exist is a published case report of severe liver injury in a man who took both drugs concurrently for cancer, along with pharmacological reasons to worry about how these drugs might interact inside the body. The question is being asked almost entirely because of social-media cancer protocols, and the honest answer is that combining these two antiparasitic drugs in humans is an uncharted experiment with documented potential for serious harm.

Why People Are Asking This Question

Interest in combining ivermectin and fenbendazole comes almost entirely from online cancer communities. Ivermectin is an antiparasitic approved for human use against conditions like river blindness and strongyloidiasis. Fenbendazole is a veterinary dewormer never approved for human use in any country. Both drugs have shown activity against cancer cells in laboratory studies, and those early-stage findings have been amplified on social media into full-blown treatment protocols, complete with dosing schedules, cycling recommendations, and combination regimens that no medical institution has validated.

A survey at MD Anderson Cancer Center identified 499 patients who reported taking ivermectin and 182 who reported taking fenbendazole as supplemental therapy between 2020 and 2024. None of these patients received prescriptions from MD Anderson for either drug. The researchers documented 154 different dosages and frequencies of ivermectin and 138 for fenbendazole across these patients, and concluded that given the enormous variation in how people were self-dosing, no conclusions about effectiveness could be drawn.¹ That finding alone should give anyone pause: hundreds of cancer patients at a world-class institution were self-administering these drugs with no consistency in dosing, guided by internet advice rather than clinical evidence.

How the Two Drugs Work

Ivermectin and fenbendazole belong to completely different drug classes and attack biological targets through different mechanisms. That distinction matters because it is the reason veterinary medicine sometimes combines them against parasites, and it is also the reason predicting their interaction in humans is not straightforward.

Ivermectin is a macrocyclic lactone. In parasites, it binds to and activates glutamate-gated chloride channels, which are ion channels found in nematode nerve and muscle cells.² When those channels get stuck in the “open” position, the parasite’s muscles become paralyzed and it dies. Mammals lack the specific type of glutamate-gated chloride channel that ivermectin targets, which is why the drug is relatively safe in humans at approved doses.

Fenbendazole is a benzimidazole. It works by binding to a structural protein called tubulin, which parasites need to build their internal scaffolding. Without functional tubulin, the worm’s cells cannot divide or maintain their shape. Laboratory research has shown that fenbendazole also destabilizes tubulin in mammalian cancer cells, though the effect is moderate compared to established chemotherapy drugs that target the same structure.³ That laboratory finding is the origin of fenbendazole’s reputation in online cancer communities, but activity in a petri dish does not translate directly to activity in a living human body, where the drug must be absorbed, reach the tumor, and achieve effective concentrations without causing unacceptable toxicity.

The Published Case of Liver Injury

The most directly relevant piece of clinical evidence is a 2025 case report describing severe drug-induced liver injury in a 65-year-old man with prostate cancer who took veterinary-grade fenbendazole and ivermectin together for three months. He had been alternating the drugs daily based on advice from online cancer support groups, using a paste syringe at a dose estimated at roughly 0.18 mg/kg of ivermectin and 0.98 mg/kg of fenbendazole per dose (described as “one squirt”).⁴

He showed up at his doctor’s office with two weeks of fatigue, yellowing skin, and abdominal pain. Blood tests revealed liver enzyme levels far above normal: his ALT was over 1,700 U/L and his AST was over 1,100 U/L, with elevated bilirubin indicating the liver was failing to process waste products properly. Doctors ruled out viral hepatitis, autoimmune liver disease, and bile duct obstruction. A standardized causality assessment scored the relationship between the drugs and the liver injury as “highly probable.” After he stopped both drugs, his liver enzyme levels dropped by more than half within nine days and returned to normal within six weeks.⁴

One case report does not prove that this combination will always cause liver damage. But it does prove that it can. And because the man was taking veterinary formulations at self-selected doses without medical monitoring, the case illustrates every major risk of the DIY approach at once: unregulated products, unmeasured doses, no blood-work surveillance, and no early warning system until symptoms became serious.

Why the Liver Is Vulnerable

Both ivermectin and fenbendazole are processed by the liver, and their metabolic pathways overlap in ways that raise pharmacological red flags. Ivermectin is metabolized primarily by an enzyme called CYP3A4, with contributions from CYP3A5 and CYP2C9.⁵ Fenbendazole is also processed through liver enzymes, and its active metabolites are known to be hepatically cleared. When two drugs compete for the same metabolic machinery, each can slow down the breakdown of the other, potentially increasing blood levels of both drugs beyond what would occur with either one alone.

Research on ivermectin’s interaction with liver enzymes has found that ivermectin itself is a weak inhibitor of several CYP enzymes, including CYP3A4. Under normal circumstances this weak inhibition is not clinically meaningful. But the concern intensifies when another drug is piling additional metabolic load onto the same system, and when neither drug’s behavior in combination has been formally studied in humans.⁵

Even something as simple as a fatty meal can shift ivermectin’s absorption. Studies in patients treated for scabies found that eating a high-fat meal increased ivermectin concentrations in the blood by roughly 18 to 25 percent compared to fasting, and the researchers flagged this increased exposure as a possible contributor to liver side effects.⁶⁷ If a meal alone can meaningfully increase ivermectin’s exposure, adding a second drug that shares the same metabolic pathway is a much larger wildcard.

Fenbendazole Is Not Approved for Human Use

This point often gets glossed over in online protocols, but it is fundamental: fenbendazole has never been through human clinical trials for any indication. It has no approved human dose, no established human safety profile, and no human-grade pharmaceutical formulation. When people take fenbendazole, they are using veterinary paste or granules manufactured for horses, dogs, or livestock. These products are not held to the same purity, concentration, or quality-control standards as human pharmaceuticals.

Fenbendazole belongs to the benzimidazole class, which does include drugs approved for human use, such as mebendazole and albendazole. Those cousins have been through rigorous testing and are prescribed by doctors for human parasitic infections. But chemical similarity does not mean interchangeability. Different members of a drug class can have very different absorption profiles, metabolic fates, and toxicity patterns. The assumption that fenbendazole is safe for humans because mebendazole is safe for humans is a leap that no regulatory agency or clinical trial has validated.

A separate case report documented liver injury in a patient with non-small cell lung cancer who self-administered fenbendazole alone, based entirely on social media information suggesting it was effective against cancer. The authors noted that sources of medical information on social media platforms are often unproven and that it is difficult for non-medical professionals to accurately evaluate complex medical claims.⁸ Liver injury from fenbendazole alone, without ivermectin in the picture, tells us that fenbendazole carries its own hepatic risks. Combining it with another liver-metabolized drug only adds uncertainty.

Toxicity Signals Beyond the Liver

Liver damage is the most dramatic documented harm, but it is not the only safety concern associated with fenbendazole. In veterinary medicine, where fenbendazole has been used for decades, reports of bone marrow toxicity have accumulated. Febantel, a prodrug that the body converts into fenbendazole, has been associated with bone marrow suppression in dogs.⁹ And a case report described a dog that developed pancytopenia, a dangerous drop in all blood cell types, after receiving high-dose fenbendazole for a suspected liver fluke infection. The dog’s bone marrow showed severe suppression of blood cell production, and despite treatment, the animal did not survive.¹⁰

Dogs are not humans, and veterinary toxicity reports do not prove human risk in a direct one-to-one way. But they do tell us that fenbendazole at higher doses can suppress the bone marrow’s ability to make blood cells, an organ system that cancer patients already have under stress from their disease and from conventional treatments like chemotherapy. A cancer patient who adds fenbendazole to an existing chemotherapy regimen, or who takes it alongside ivermectin without monitoring blood counts, would have no way of detecting early bone marrow suppression until symptoms like infections, bruising, or extreme fatigue appeared.

Where Combining These Drugs Actually Has Evidence

There is one area where pairing a macrocyclic lactone like ivermectin with a benzimidazole like fenbendazole is backed by research: livestock parasite control. In veterinary parasitology, combining anthelmintics from different classes with different mechanisms of action is a well-studied strategy for managing drug-resistant worm populations. The logic is straightforward: if worms have developed resistance to one drug class, a second drug working through a different mechanism can still kill them. Combination products containing a macrocyclic lactone and a benzimidazole are commercially available in several countries for deworming sheep and cattle.¹¹

Research in cattle has demonstrated that concurrent treatment with a macrocyclic lactone and a benzimidazole provided season-long advantages in controlling nematode populations, particularly when the parasites had already developed resistance to macrocyclic lactones alone.¹² Combination strategies are also advocated as a way to slow the emergence of resistance to newer anthelmintic classes by pairing them with older ones that still retain some efficacy.¹³

This veterinary precedent is sometimes cited in online communities as evidence that combining ivermectin and fenbendazole is a known, safe practice. But the veterinary context is entirely different from self-treatment for cancer. In livestock, these drugs are used at established doses, for a proven indication (killing parasites), in species where the pharmacokinetics are well characterized. The safety margins, dosing schedules, and drug formulations are all species-specific. Extrapolating from a sheep deworming protocol to a human cancer treatment protocol is not supported by any of this research.

The Gap Between Lab Results and Human Treatment

Both ivermectin and fenbendazole have shown anticancer activity in cell cultures and, to a limited extent, in animal models. Fenbendazole disrupts microtubules in cancer cells and appears to affect several pathways involved in cell survival and growth.³ Ivermectin has been reported to affect cancer cells through mechanisms distinct from its antiparasitic action. These findings are genuinely interesting from a drug-repurposing perspective, and researchers have noted them as worth pursuing.

But the distance between a drug killing cancer cells in a dish and a drug safely treating cancer in a person is enormous. Most compounds that show anticancer activity in the lab fail in clinical trials. They fail because they cannot reach the tumor in sufficient concentration, or because effective doses are toxic to normal tissues, or because the living body compensates in ways that cancel out the drug’s effect. Neither ivermectin nor fenbendazole has completed the kind of controlled human trial that would answer the basic questions: does it work in people, at what dose, with what side effects, and for which cancers?

Experimental work has explored delivering both drugs in nanosuspension form for neurocysticercosis, a parasitic brain infection, with the goal of improving penetration across the blood-brain barrier.¹⁴ This is the kind of careful, stepwise research that drug development requires. It is a long way from a clinical treatment recommendation, and it addresses a parasitic infection, not cancer.

What Self-Treating Actually Looks Like

The MD Anderson survey paints a striking picture of how chaotic self-treatment with these drugs has become. Among just the patients who visited that single cancer center over four years, there were nearly 300 different dosing patterns reported across the two drugs.¹ Some patients took them daily, some weekly, some cycled on and off. Doses varied wildly. This is not a clinical protocol being replicated across patients. It is a collection of individual experiments, each one an n-of-one trial with no controls, no blinding, and no systematic safety monitoring.

When people describe their regimens online, they often cite anecdotal success stories: someone’s tumor shrank, someone’s markers dropped. These stories are powerful but scientifically unreliable. Cancer patients are almost always receiving conventional treatment simultaneously, making it impossible to attribute any change to the antiparasitic drugs. People whose tumors progressed or who experienced serious side effects are less likely to post about it, creating a skewed sample of apparent successes. And the natural variation in cancer outcomes means that some patients will improve regardless of what supplements they add.

If your oncologist does not know you are taking these drugs, the consequences extend beyond the drugs themselves. Ivermectin’s interactions with liver enzymes could potentially alter the metabolism of chemotherapy agents, changing the effective dose of your actual cancer treatment. If liver enzyme elevations show up on routine blood work, your oncologist might delay or reduce your chemotherapy based on what looks like liver toxicity from the chemo, when the real cause is an undisclosed antiparasitic regimen. The downstream effects of secret self-treatment ripple through the entire treatment plan.

Ongoing Research and What It Does Not Yet Show

Researchers are aware of the public interest in these drugs and the gap in clinical data. The preclinical studies are real science, conducted by real researchers, published in peer-reviewed journals. The problem is not that the science is fabricated. It is that the science is early-stage and has been leapfrogged by patient demand. In drug development, cell-culture findings lead to animal studies, which lead to phase I safety trials, dose-finding trials, and eventually large randomized controlled trials. Ivermectin and fenbendazole as cancer treatments are still somewhere in the cell-culture-to-animal-model range. The controlled human trials that would tell us whether these drugs help, hurt, or do nothing for cancer patients have not been completed.

Some researchers have begun to study ivermectin and fenbendazole nanosuspensions together in animal models of parasitic disease, exploring whether improved drug delivery can enhance antiparasitic effects while reducing inflammation.¹⁴ This kind of work may eventually generate combination safety and efficacy data, but it is aimed at parasitic infection, uses carefully formulated drug preparations rather than veterinary pastes, and is still in the animal testing stage. It does not support any human dosing decisions today.

For people who want to participate in advancing the science, the path runs through clinical trials, not self-experimentation. If a controlled trial eventually enrolls patients to test these drugs against cancer, that trial will include dose selection based on pharmacokinetic modeling, regular blood-work monitoring for liver and bone marrow toxicity, and the ability to detect and respond to adverse events quickly. None of those safeguards exist when you squeeze a dose of horse paste from a tube in your kitchen.